Drugs / Tetrathiomolybdate
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01837329 | Nov 2013 → Jan 2019 | non-small cell lung carcinoma | University of Rochester | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06134375 | Nov 2024 → Jun 2031 expected | triple-negative breast carcinoma | Dartmouth-Hitchcock Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00189176 | Mar 2003 → May 2006 | idiopathic pulmonary fibrosis | University of Michigan | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT00113542 | Jun 2004 → Jun 2005 | psoriasis | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT00195091 | Dec 2003 → Mar 2023 | breast cancer | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00176800 | Nov 2001 → Feb 2006 | carcinoma of esophagus | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00150995 | May 2001 → Oct 2003 | prostate cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00176774 | Feb 2001 → Feb 2004 | colorectal carcinoma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00006332 | — | hepatocellular carcinoma | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00805805 | Apr 2006 → Dec 2008 | primary biliary cholangitis | George Brewer | Completed | No outcome recorded |
| Phase 3 | NCT00004339 | Jan 1994 → ? | Wilson disease | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetrathiomolybdate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006332 ↗ |
| Known as | Ammonium tetrathiomolybdate | “Tetrathiomolybdate (TM): Ammonium tetrathiomolybdate (TM), an oral copper lowering agent, has been established as safe in patients with Wilson's disease and advanced cancer.” NCT06134375 ↗ |
| Route | Oral | “one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime” NCT00176774 ↗ |